Problems associated with prophylactic use of erythromycin in 1566 staff to prevent hospital infection during the outbreak of pertussis

H. Tanaka, M. Kaji, K. Higuchi, N. Shinohara, M. Norimatsu, Hitoshi Kawazoe, M. Ninomiya, N. Fukuoka, N. Ishii, J. Fujita, A. Okabe, H. Houchi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background and objective: Pertussis developed in Kagawa University Medical School and University Hospital in May 2007. To control the outbreak and prevent the infection of hospital inpatients, the Infection Control Team (ICT) carried out the prophylactic administration of erythromycin (EM) to hospital staff (1566 staff) who might be exposed to Bordetella pertussis. Methods: An oral dose of 1000 mg/day EM was given for 10 days. To assess compliance and estimate the frequency of adverse effect, the ICT conducted a questionnaire survey. Results and discussion: Of 942 respondents (response rate: 60·2%), 264 (28·0%) experienced some form of EM adverse effects, of which the most commonly reported involved digestive organ symptoms, e.g. diarrhoea (15·6%), stomachache (7·5%), nausea (3·6%), epigastric distress (2·1%) and abdominal distention (1·8%). More importantly, 246 participants (26·1%) stopped taking the EM before completing 10 days because of perceived adverse effects. Conclusion: These results indicate that EM appears to cause adverse effects more frequently than reported in the package insert in Japan. The prophylactic use of EM for pertussis infection is recognized in the guideline of the Centers for Disease Control and Prevention. However, this study suggests that attention should be paid to EM non-compliance during a pertussis outbreak, which could extend the duration of the outbreak and increase the number of affected patients.

Original languageEnglish
Pages (from-to)719-722
Number of pages4
JournalJournal of Clinical Pharmacy and Therapeutics
Volume34
Issue number6
DOIs
Publication statusPublished - 2009 Dec 1
Externally publishedYes

Fingerprint

Whooping Cough
Erythromycin
Cross Infection
Disease Outbreaks
Infection Control
Product Labeling
Bordetella pertussis
Centers for Disease Control and Prevention (U.S.)
Medical Schools
Nausea
Compliance
Inpatients
Diarrhea
Japan
Guidelines
Infection

Keywords

  • Adverse effect
  • Erythromycin
  • Infection control team
  • Outbreak
  • Pertussis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Problems associated with prophylactic use of erythromycin in 1566 staff to prevent hospital infection during the outbreak of pertussis. / Tanaka, H.; Kaji, M.; Higuchi, K.; Shinohara, N.; Norimatsu, M.; Kawazoe, Hitoshi; Ninomiya, M.; Fukuoka, N.; Ishii, N.; Fujita, J.; Okabe, A.; Houchi, H.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 34, No. 6, 01.12.2009, p. 719-722.

Research output: Contribution to journalArticle

Tanaka, H, Kaji, M, Higuchi, K, Shinohara, N, Norimatsu, M, Kawazoe, H, Ninomiya, M, Fukuoka, N, Ishii, N, Fujita, J, Okabe, A & Houchi, H 2009, 'Problems associated with prophylactic use of erythromycin in 1566 staff to prevent hospital infection during the outbreak of pertussis', Journal of Clinical Pharmacy and Therapeutics, vol. 34, no. 6, pp. 719-722. https://doi.org/10.1111/j.1365-2710.2009.01060.x
Tanaka, H. ; Kaji, M. ; Higuchi, K. ; Shinohara, N. ; Norimatsu, M. ; Kawazoe, Hitoshi ; Ninomiya, M. ; Fukuoka, N. ; Ishii, N. ; Fujita, J. ; Okabe, A. ; Houchi, H. / Problems associated with prophylactic use of erythromycin in 1566 staff to prevent hospital infection during the outbreak of pertussis. In: Journal of Clinical Pharmacy and Therapeutics. 2009 ; Vol. 34, No. 6. pp. 719-722.
@article{85c51e54c180462384fb86586a7c4dcb,
title = "Problems associated with prophylactic use of erythromycin in 1566 staff to prevent hospital infection during the outbreak of pertussis",
abstract = "Background and objective: Pertussis developed in Kagawa University Medical School and University Hospital in May 2007. To control the outbreak and prevent the infection of hospital inpatients, the Infection Control Team (ICT) carried out the prophylactic administration of erythromycin (EM) to hospital staff (1566 staff) who might be exposed to Bordetella pertussis. Methods: An oral dose of 1000 mg/day EM was given for 10 days. To assess compliance and estimate the frequency of adverse effect, the ICT conducted a questionnaire survey. Results and discussion: Of 942 respondents (response rate: 60·2{\%}), 264 (28·0{\%}) experienced some form of EM adverse effects, of which the most commonly reported involved digestive organ symptoms, e.g. diarrhoea (15·6{\%}), stomachache (7·5{\%}), nausea (3·6{\%}), epigastric distress (2·1{\%}) and abdominal distention (1·8{\%}). More importantly, 246 participants (26·1{\%}) stopped taking the EM before completing 10 days because of perceived adverse effects. Conclusion: These results indicate that EM appears to cause adverse effects more frequently than reported in the package insert in Japan. The prophylactic use of EM for pertussis infection is recognized in the guideline of the Centers for Disease Control and Prevention. However, this study suggests that attention should be paid to EM non-compliance during a pertussis outbreak, which could extend the duration of the outbreak and increase the number of affected patients.",
keywords = "Adverse effect, Erythromycin, Infection control team, Outbreak, Pertussis",
author = "H. Tanaka and M. Kaji and K. Higuchi and N. Shinohara and M. Norimatsu and Hitoshi Kawazoe and M. Ninomiya and N. Fukuoka and N. Ishii and J. Fujita and A. Okabe and H. Houchi",
year = "2009",
month = "12",
day = "1",
doi = "10.1111/j.1365-2710.2009.01060.x",
language = "English",
volume = "34",
pages = "719--722",
journal = "Journal of Clinical Pharmacy and Therapeutics",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Problems associated with prophylactic use of erythromycin in 1566 staff to prevent hospital infection during the outbreak of pertussis

AU - Tanaka, H.

AU - Kaji, M.

AU - Higuchi, K.

AU - Shinohara, N.

AU - Norimatsu, M.

AU - Kawazoe, Hitoshi

AU - Ninomiya, M.

AU - Fukuoka, N.

AU - Ishii, N.

AU - Fujita, J.

AU - Okabe, A.

AU - Houchi, H.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Background and objective: Pertussis developed in Kagawa University Medical School and University Hospital in May 2007. To control the outbreak and prevent the infection of hospital inpatients, the Infection Control Team (ICT) carried out the prophylactic administration of erythromycin (EM) to hospital staff (1566 staff) who might be exposed to Bordetella pertussis. Methods: An oral dose of 1000 mg/day EM was given for 10 days. To assess compliance and estimate the frequency of adverse effect, the ICT conducted a questionnaire survey. Results and discussion: Of 942 respondents (response rate: 60·2%), 264 (28·0%) experienced some form of EM adverse effects, of which the most commonly reported involved digestive organ symptoms, e.g. diarrhoea (15·6%), stomachache (7·5%), nausea (3·6%), epigastric distress (2·1%) and abdominal distention (1·8%). More importantly, 246 participants (26·1%) stopped taking the EM before completing 10 days because of perceived adverse effects. Conclusion: These results indicate that EM appears to cause adverse effects more frequently than reported in the package insert in Japan. The prophylactic use of EM for pertussis infection is recognized in the guideline of the Centers for Disease Control and Prevention. However, this study suggests that attention should be paid to EM non-compliance during a pertussis outbreak, which could extend the duration of the outbreak and increase the number of affected patients.

AB - Background and objective: Pertussis developed in Kagawa University Medical School and University Hospital in May 2007. To control the outbreak and prevent the infection of hospital inpatients, the Infection Control Team (ICT) carried out the prophylactic administration of erythromycin (EM) to hospital staff (1566 staff) who might be exposed to Bordetella pertussis. Methods: An oral dose of 1000 mg/day EM was given for 10 days. To assess compliance and estimate the frequency of adverse effect, the ICT conducted a questionnaire survey. Results and discussion: Of 942 respondents (response rate: 60·2%), 264 (28·0%) experienced some form of EM adverse effects, of which the most commonly reported involved digestive organ symptoms, e.g. diarrhoea (15·6%), stomachache (7·5%), nausea (3·6%), epigastric distress (2·1%) and abdominal distention (1·8%). More importantly, 246 participants (26·1%) stopped taking the EM before completing 10 days because of perceived adverse effects. Conclusion: These results indicate that EM appears to cause adverse effects more frequently than reported in the package insert in Japan. The prophylactic use of EM for pertussis infection is recognized in the guideline of the Centers for Disease Control and Prevention. However, this study suggests that attention should be paid to EM non-compliance during a pertussis outbreak, which could extend the duration of the outbreak and increase the number of affected patients.

KW - Adverse effect

KW - Erythromycin

KW - Infection control team

KW - Outbreak

KW - Pertussis

UR - http://www.scopus.com/inward/record.url?scp=70450171362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450171362&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2710.2009.01060.x

DO - 10.1111/j.1365-2710.2009.01060.x

M3 - Article

C2 - 20175806

AN - SCOPUS:70450171362

VL - 34

SP - 719

EP - 722

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

SN - 0269-4727

IS - 6

ER -